We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
COVID-19 vaccine typedependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
- Authors
Jung Yeon Heo; Yu Bin Seo; Eun Jin Kim; Jacob Lee; Young Rong Kim; Jin Gu Yoon; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Soo-Young Yoon; Ju-Yeon Choi; Young Jae Lee; Hye Won Lee; Sung Soon Kim; Byoungguk Kim; Joon Young Song
- Abstract
Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines. Here, we evaluated the association between reactogenicity and immunogenicity in healthy adults following vaccination by analyzing blood samples before and after sequential two-dose vaccinations of BNT162b2 and ChAdOx1 nCoV-19. Outcomes included anti-S IgG antibody and neutralizing antibody responses, adverse events, and proinflammatory cytokine responses. A total of 59 and 57 participants vaccinated with BNT162b2 and ChAdOx1 nCoV-19, respectively, were enrolled. Systemic adverse events were more common after the first ChAdOx1 nCoV-19 dose than after the second. An opposite trend was observed in BNT162b2 recipients. Although the first ChAdOx1 nCoV-19 dose significantly elevated the median proinflammatory cytokine levels, the second dose did not, and neither did either dose of BNT162b2. Grades of systemic adverse events in ChAdOx1 nCoV-19 recipients were significantly associated with IL-6 and IL-1b levels. Anti-S IgG and neutralizing antibody titers resulting from the second BNT162b2 dose were significantly associated with fever. In conclusion, systemic adverse events resulting from the first ChAdOx1 nCoV-19 dose may be associated with proinflammatory cytokine responses rather than humoral immune responses. Febrile reactions after second BNT162b2 dose were positively correlated with vaccine-induced immune responses rather than with inflammatory responses.
- Subjects
IMMUNE response; COVID-19 vaccines; COVID-19; VACCINE immunogenicity; INFLAMMATION
- Publication
Frontiers in Immunology, 2022, Vol 13, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2022.975363